These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3292181)

  • 41. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-Candida drugs--the biochemical basis for their activity.
    Vanden Bossche H; Willemsens G; Marichal P
    Crit Rev Microbiol; 1987; 15(1):57-72. PubMed ID: 3319421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative in vitro effect of 7 quinolones on Ureaplasma urealyticum].
    Cantet P; Renaudin H; Quentin C; Bebear C
    Pathol Biol (Paris); 1983 Jun; 31(6):501-3. PubMed ID: 6224125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Isolation, identification and drug-resistance of nosocomial yeasts].
    Alegente G; Gonnelli A; Galgani P; Boggiano CA
    Ann Sclavo; 1982; 24(2):103-13. PubMed ID: 6763853
    [No Abstract]   [Full Text] [Related]  

  • 45. Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.
    Beggs WH; Sarosi GA; Steele NM
    Antimicrob Agents Chemother; 1976 Jun; 9(6):863-5. PubMed ID: 779631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C; Richmond S; Bailey J
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract]   [Full Text] [Related]  

  • 47. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
    Ridgway GL; Mumtaz G; Gabriel FG; Oriel JD
    Eur J Clin Microbiol; 1984 Aug; 3(4):344-6. PubMed ID: 6237903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics.
    Brajtburg J; Kobayashi D; Medoff G; Kobayashi GS
    J Infect Dis; 1982 Aug; 146(2):138-46. PubMed ID: 6286784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).
    Medoff G; Kobayashi GS; Kwan CN; Schlessinger D; Venkov P
    Proc Natl Acad Sci U S A; 1972 Jan; 69(1):196-9. PubMed ID: 4550505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.
    Vakil R; Knilans K; Andes D; Kwon GS
    Pharm Res; 2008 Sep; 25(9):2056-64. PubMed ID: 18415047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro.
    Scheven M; Schwegler F
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1779-83. PubMed ID: 7486918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dependence of vacuole disruption and independence of potassium ion efflux in fungicidal activity induced by combination of amphotericin B and allicin against Saccharomyces cerevisiae.
    Ogita A; Yutani M; Fujita K; Tanaka T
    J Antibiot (Tokyo); 2010 Dec; 63(12):689-92. PubMed ID: 20940723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of adherence of Candida albicans by conventional and experimental antifungal drugs.
    Vuddhakul V; McCormack JG; Seow WK; Smith SE; Thong YH
    J Antimicrob Chemother; 1988 Jun; 21(6):755-63. PubMed ID: 3045068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Problems in the laboratory assessment of antifungal activity.
    Odds FC
    Postgrad Med J; 1979 Sep; 55(647):677-80. PubMed ID: 392483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
    Traub WH
    Chemotherapy; 1984; 30(6):379-86. PubMed ID: 6097410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
    Edlund C; Nord CE
    Infection; 1988; 16(1):8-12. PubMed ID: 3283041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nalidixic acid analogues and Shigella.
    Bannatyne RM; Toma S; Cheung R
    Lancet; 1984 Jul; 2(8395):172-3. PubMed ID: 6146075
    [No Abstract]   [Full Text] [Related]  

  • 59. Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans.
    Scalarone GM; Mikami Y; Kurita N; Ichihara Y; Yazawa K; Miyaji M
    Mycoses; 1991; 34(7-8):297-302. PubMed ID: 1803230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction between quinolones and caffeine.
    Staib AH; Stille W; Dietlein G; Shah PM; Harder S; Mieke S; Beer C
    Drugs; 1987; 34 Suppl 1():170-4. PubMed ID: 3481318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.